New Probe Detects Fusion of bcr/abl

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

DOWNERS GROVE, Ill--Vysis Inc. has announced the availability of the Locus Specific Identifier (LSITM) bcr/abl translocation probe, a dual-color probe mixture that detects gene fusion of the bcr and abl genes.

DOWNERS GROVE, Ill--Vysis Inc. has announced the availabilityof the Locus Specific Identifier (LSITM) bcr/abl translocationprobe, a dual-color probe mixture that detects gene fusion ofthe bcr and abl genes.

This translocation has been associated with chronic myelogenousleukemia (CML) and acute lymphocytic leukemia (ALL).

The new probe, which is for research use only, is based on proprietaryapplications of FISH (fluorescence in situ hybridization) technology.The probe directly detects target DNA by hybridizing to specificlocations on individual chromosomes, the company said.

Bright Fluorescent Signal

Following hybridization, a bright fluorescent signal is emittedthat can be observed with use of a fluorescence microscope andimaging systems (see figure).

The LSI bcr/abl probe consists of a single probe for bcr (breakpointcluster region), directly labeled with the SpectrumGreenTM fluorochrome,and another probe for the Abelson oncogene (c-abl), directly labeledwith the Spec- trumOrangeTM fluorochrome.

The assay allows the user to quantitatively evaluate both probessimultaneously, either in interphase nuclei or metaphase cells.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content